Medical Access Program for DS-9606a (DS-9606) in Patients With Advanced Testicular Germ Cell Tumors
brief summary
DS-9606a demonstrates antitumor activity in patients with solid tumors known to express CLDN-6, primarily in patients with testicular GCT, with a manageable safety profile with appropriate risk minimization measures. The purpose of this Medical Access Program (MAP) is to provide access to DS-9606a to eligible patients with advanced testicular GCT who have received standard of care treatment and, in their treating physician's opinion, have an unmet clinical need and cannot enter a clinical trial.
detailed description
A patient enrolled in the MAP can continue treatment until any of the following occurs, whichever comes first:
* Disease progression * Unacceptable toxicity * The benefit-risk no longer favors the individual * DS-9606a becomes commercially available in the US, or other treatment options become available * Withdrawal of consent to continue treatment * Physician discretion * Death * The physician determines that it is in the patient's best interest to stop therapy * Sponsor decision to terminate the MAP
official title
Medical Access Program for DS-9606a (DS-9606) for the Treatment of Patients With Advanced Testicular Germ Cell Tumors